Replies to post #3847 on Biotech Values

[DewDiligence]

MRVT selects product name for Visudyne-like AMD drug:

[Photrex may be a catchy name (I said “may”) but it’s still just photodynamic therapy and it’s doubtful that it will offer much benefit relative to Visudyne. A few days ago, the FDA requested that MRVT conduct an additional clinical study (#msg-4174396).]

http://biz.yahoo.com/bw/041006/65323_1.html

>>
Miravant Announces PHOTREX as New Brand Name For SnET2 PDT

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Oct. 6, 2004--Miravant Medical Technologies (OTCBB:MRVT), a pharmaceutical development company specializing in photodynamic therapy (PDT), today announced PHOTREX(TM) as the new brand name for SnET2, a proposed PDT drug for the treatment of wet age-related macular degeneration (AMD).

The Company also announced that the United States Adopted Name Council (USAN) has designated "rostaporfin" as the drug's unique generic name. USAN is the agency that assigns generic names to pharmaceuticals.

"We believe that PHOTREX is a powerful and distinctive brand name for SnET2 photodynamic therapy," stated Gary S. Kledzik, Ph.D., chairman and chief executive officer. On September 30, 2004, the U.S. Food and Drug Administration (FDA) issued an approvable letter for PHOTREX outlining the conditions for final marketing approval, which included a request for an additional confirmatory clinical trial.
<<